Oxford, UK-based Exscientia has been working with German biotech Evotec on the adenosine A2a receptor antagonist, which is being tested as a treatment for adult patients with advanced solid tumours.

KW-6356 has a higher affinity and selectivity for adenosine A2A receptors, leading Kyowa Kiri to speculate that it could obtain approval for a wider group of Parkinson's patients than Nourianz.

Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist ... first time two highly selective A2A and A2B antagonists are combined in patients ...

The final structure of the adenosine A2A receptor was examined in the study. The yellow spheres are sulfur atoms, the blue spheres are water molecules, and the blue lines represent the lipid membrane.

Portage Biotech (PRTG) presented new preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor. The new data demonstrate both ...

Combining PORT-6 and PORT-7 for a More Comprehensive Immunotherapy Approach ...

To our knowledge, this is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor ... two highly selective A2A and A2B antagonists are combined ...